Ribavirin, Its Dosing Regime

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily, instead of twice daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maastricht University Medical Center
• Collaborator: Roche Pharma AG
• Treatments: Ribavirin

Criteria

Inclusion Criteria:

• anti-HCV positivity > 6 months

• Positive HCV-RNA genotype 1 or 4

• Liver biopsy within one year before the start of therapy

• Intention to be treated and participate treatment

• body weight at or above 75 kg

Exclusion Criteria:

• HIV positive